-DOCSTART- -X- O
The -X- _ O
severe -X- _ B-Patient
acute -X- _ I-Patient
respiratory -X- _ I-Patient
syndromeâ€“associated -X- _ I-Patient
coronavirus -X- _ I-Patient
( -X- _ I-Patient
SARS-CoV -X- _ I-Patient
) -X- _ I-Patient
spike -X- _ I-Patient
protein -X- _ I-Patient
( -X- _ I-Patient
S -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
a -X- _ O
major -X- _ O
target -X- _ O
for -X- _ O
neutralizing -X- _ B-Intervention
antibodies. -X- _ I-Intervention
Retroviral -X- _ B-Patient
SARS-CoV -X- _ I-Patient
S -X- _ I-Patient
pseudotypes -X- _ I-Patient
have -X- _ O
been -X- _ O
constructed -X- _ O
and -X- _ O
used -X- _ O
to -X- _ O
develop -X- _ O
an -X- _ O
in -X- _ O
vitro -X- _ O
microneutralization -X- _ O
assay -X- _ O
that -X- _ O
is -X- _ O
both -X- _ O
sensitive -X- _ O
and -X- _ O
specific -X- _ O
for -X- _ O
SARS-CoV -X- _ B-Intervention
neutralizing -X- _ I-Intervention
antibodies. -X- _ I-Intervention
Neutralization -X- _ O
titers -X- _ O
measured -X- _ O
by -X- _ O
this -X- _ O
assay -X- _ O
are -X- _ O
highly -X- _ O
correlated -X- _ O
to -X- _ O
those -X- _ O
measured -X- _ O
by -X- _ O
an -X- _ O
assay -X- _ O
using -X- _ O
replication-competent -X- _ O
SARS-CoV. -X- _ O
No -X- _ B-Outcome
cross-neutralization -X- _ I-Outcome
occurred -X- _ I-Outcome
with -X- _ I-Outcome
human -X- _ I-Outcome
sera -X- _ I-Outcome
known -X- _ I-Outcome
to -X- _ I-Outcome
contain -X- _ I-Outcome
antibodies -X- _ I-Outcome
to -X- _ I-Outcome
coronavirus -X- _ I-Outcome
strains -X- _ I-Outcome
OC43 -X- _ I-Outcome
and -X- _ I-Outcome
229E. -X- _ I-Outcome
The -X- _ O
pseudotype -X- _ O
assay -X- _ O
was -X- _ O
used -X- _ O
to -X- _ O
profile -X- _ O
neutralizing -X- _ B-Intervention
antibody -X- _ I-Intervention
responses -X- _ I-Intervention
against -X- _ O
SARS-CoV -X- _ B-Patient
S -X- _ I-Patient
in -X- _ I-Patient
sequential -X- _ I-Patient
serum -X- _ I-Patient
samples -X- _ I-Patient
taken -X- _ I-Patient
from -X- _ I-Patient
41 -X- _ I-Patient
confirmed -X- _ I-Patient
SARS -X- _ I-Patient
patients -X- _ I-Patient
during -X- _ O
the -X- _ O
2003 -X- _ O
outbreak -X- _ O
in -X- _ O
Hong -X- _ O
Kong -X- _ O
and -X- _ O
shows -X- _ O
long-lasting -X- _ B-Outcome
immunity -X- _ I-Outcome
in -X- _ I-Outcome
most -X- _ I-Outcome
recovered -X- _ I-Outcome
patients. -X- _ I-Outcome
The -X- _ O
pseudotype -X- _ O
assay -X- _ O
does -X- _ O
not -X- _ O
require -X- _ O
handling -X- _ O
live -X- _ O
SARS -X- _ O
virus -X- _ O
; -X- _ O
it -X- _ O
is -X- _ O
a -X- _ O
useful -X- _ O
tool -X- _ O
to -X- _ O
determine -X- _ O
neutralizing -X- _ O
titers -X- _ O
during -X- _ O
natural -X- _ O
infection -X- _ O
and -X- _ O
the -X- _ O
preclinical -X- _ O
evaluation -X- _ O
of -X- _ O
candidate -X- _ O
vaccines -X- _ O
. -X- _ O

